Diarrhea - Pipeline Review, H2 2017

Date: July 11, 2017
Pages: 146
Price:
US$ 2,000.00
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: DAA06A1D26DEN
Leaflet:

Download PDF Leaflet

Diarrhea - Pipeline Review, H2 2017
Diarrhea - Pipeline Review, H2 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Diarrhea - Pipeline Review, H2 2017, provides an overview of the Diarrhea (Gastrointestinal) pipeline landscape.

Diarrhea is a contagious gastrointestinal infection occurring mostly due to unhygienic conditions. Diarrhea may be related to a viral or bacterial infection and is sometimes the result of food poisoning. Symptoms include nausea, abdominal pain, cramping, bloating, dehydration, fever, bloody stools, frequent urge to evacuate the bowels and incontinence. Treatment includes medication and healthy lifestyle.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Diarrhea - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Diarrhea (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Diarrhea (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Diarrhea and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 7, 10, 2, 1, 21 and 4 respectively. Similarly, the Universities portfolio in Phase I and Preclinical stages comprises 2 and 4 molecules, respectively.

Diarrhea (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.Scope
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Diarrhea (Gastrointestinal).
  • The pipeline guide reviews pipeline therapeutics for Diarrhea (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Diarrhea (Gastrointestinal) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Diarrhea (Gastrointestinal) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Diarrhea (Gastrointestinal)
Reasons to buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Diarrhea (Gastrointestinal).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Diarrhea (Gastrointestinal) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Introduction
Global Markets Direct Report Coverage
Diarrhea - Overview
Diarrhea - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Diarrhea - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Diarrhea - Companies Involved in Therapeutics Development
A. Menarini Industrie Farmaceutiche Riunite Srl
Actelion Ltd
Aegis Therapeutics LLC
Akthelia Pharmaceuticals Ltd
Albireo Pharma Inc
Allergan Plc
Anatara Lifesciences Limited
Ardelyx Inc
Assembly Biosciences Inc
AzurRx BioPharma Inc
Bharat Biotech International Ltd
Cosmo Pharmaceuticals NV
DiscoveryBiomed Inc
GP Pharm SA
Miyarisan Pharmaceutical Company Ltd
Mucosis BV
Napo Pharmaceuticals Inc
Nippon Shinyaku Co Ltd
Novartis AG
Pfizer Inc
Prokarium Ltd
Rebiotix Inc
Recce Ltd
RedHill Biopharma Ltd
RxBio Inc
Scandinavian Biopharma Holding AB
Sigmoid Pharma Ltd
Summit Therapeutics Plc
Synthetic Biologics Inc
Syntiron LLC
Tasly Pharmaceutical Group Co Ltd
Wuhan Institute of Biological Products Co Ltd
Diarrhea - Drug Profiles
ABIM-101 - Drug Profile
AKT-10081 - Drug Profile
ASP-7147 - Drug Profile
AZX-1101 - Drug Profile
Biologic for Irritable Bowel Syndrome with Diarrhea - Drug Profile
cadazolid - Drug Profile
Campylobacter jejuni [strain CPS81-176] vaccine - Drug Profile
CBM-588 - Drug Profile
cholestyramine - Drug Profile
crofelemer DR - Drug Profile
Drugs for Irritable Bowel Syndrome with Diarrhea - Drug Profile
Escherichia coli vaccine - Drug Profile
ETEC vaccine - Drug Profile
ETEC vaccine - Drug Profile
Etvax - Drug Profile
GXG-8 - Drug Profile
ibodutant - Drug Profile
IMSUTMR-1501 - Drug Profile
infectious diarrhea [serotype H11] vaccine - Drug Profile
LJN-452 - Drug Profile
octreotide acetate - Drug Profile
octreotide acetate MAR - Drug Profile
ondansetron hydrochloride CR - Drug Profile
ORP-101 - Drug Profile
Peptide to Activate NHE-3 for Diarrhea - Drug Profile
PF-06425090 - Drug Profile
prulifloxacin - Drug Profile
PZ-7475 - Drug Profile
RBX-2660 - Drug Profile
RDX-023 - Drug Profile
RDX-98940 - Drug Profile
RECCE-355 - Drug Profile
Recombinant Enzyme for Diarrhea - Drug Profile
ribaxamase - Drug Profile
ridinilazole - Drug Profile
rifamycin CR - Drug Profile
Rotavac-5C - Drug Profile
rotavirus [serotypes G1, G2, G3, G4, G8, G9] (hexavalent) vaccine - Drug Profile
Rx-100 - Drug Profile
Small Molecule for Infectious Diarrhea and Necrotizing Enterocolitis - Drug Profile
Small Molecule to Inhibit EnaC and CFTR for Cystic Fibrosis, Secretory Diarrhea and Autosomal Dominant Polycystic Kidney Disease - Drug Profile
Small Molecules to Inhibit Beta-Glucuronidase for Chemotherapy Induced Diarrhea - Drug Profile
SYN-006 - Drug Profile
SYN-007 - Drug Profile
thuricin CD - Drug Profile
Typhetec - Drug Profile
Vaccine 1 for Diarrhea - Drug Profile
Vaccine 2 for Diarrhea - Drug Profile
Vaccine for Traveler's Diarrhea - Drug Profile
Vaccine for Traveler's Diarrhea - Drug Profile
Yersinia pestis vaccine - Drug Profile
Diarrhea - Dormant Projects
Diarrhea - Discontinued Products
Diarrhea - Product Development Milestones
Featured News & Press Releases
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

LIST OF TABLES

Number of Products under Development for Diarrhea, H2 2017
Number of Products under Development by Companies, H2 2017
Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017
Number of Products under Development by Companies, H2 2017 (Contd..2), H2 2017
Number of Products under Development by Universities/Institutes, H2 2017
Products under Development by Companies, H2 2017
Products under Development by Companies, H2 2017 (Contd..1), H2 2017
Products under Development by Companies, H2 2017 (Contd..2), H2 2017
Products under Development by Universities/Institutes, H2 2017
Number of Products by Stage and Target, H2 2017
Number of Products by Stage and Target, H2 2017 (Contd..1), H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017
Number of Products by Stage and Route of Administration, H2 2017
Number of Products by Stage and Molecule Type, H2 2017
Diarrhea - Pipeline by A. Menarini Industrie Farmaceutiche Riunite Srl, H2 2017
Diarrhea - Pipeline by Actelion Ltd, H2 2017
Diarrhea - Pipeline by Aegis Therapeutics LLC, H2 2017
Diarrhea - Pipeline by Akthelia Pharmaceuticals Ltd, H2 2017
Diarrhea - Pipeline by Albireo Pharma Inc, H2 2017
Diarrhea - Pipeline by Allergan Plc, H2 2017
Diarrhea - Pipeline by Anatara Lifesciences Limited, H2 2017
Diarrhea - Pipeline by Ardelyx Inc, H2 2017
Diarrhea - Pipeline by Assembly Biosciences Inc, H2 2017
Diarrhea - Pipeline by AzurRx BioPharma Inc, H2 2017
Diarrhea - Pipeline by Bharat Biotech International Ltd, H2 2017
Diarrhea - Pipeline by Cosmo Pharmaceuticals NV, H2 2017
Diarrhea - Pipeline by DiscoveryBiomed Inc, H2 2017
Diarrhea - Pipeline by GP Pharm SA, H2 2017
Diarrhea - Pipeline by Miyarisan Pharmaceutical Company Ltd, H2 2017
Diarrhea - Pipeline by Mucosis BV, H2 2017
Diarrhea - Pipeline by Napo Pharmaceuticals Inc, H2 2017
Diarrhea - Pipeline by Nippon Shinyaku Co Ltd, H2 2017
Diarrhea - Pipeline by Novartis AG, H2 2017
Diarrhea - Pipeline by Pfizer Inc, H2 2017
Diarrhea - Pipeline by Prokarium Ltd, H2 2017
Diarrhea - Pipeline by Rebiotix Inc, H2 2017
Diarrhea - Pipeline by Recce Ltd, H2 2017
Diarrhea - Pipeline by RedHill Biopharma Ltd, H2 2017
Diarrhea - Pipeline by RxBio Inc, H2 2017
Diarrhea - Pipeline by Scandinavian Biopharma Holding AB, H2 2017
Diarrhea - Pipeline by Sigmoid Pharma Ltd, H2 2017
Diarrhea - Pipeline by Summit Therapeutics Plc, H2 2017
Diarrhea - Pipeline by Synthetic Biologics Inc, H2 2017
Diarrhea - Pipeline by Syntiron LLC, H2 2017
Diarrhea - Pipeline by Tasly Pharmaceutical Group Co Ltd, H2 2017
Diarrhea - Pipeline by Wuhan Institute of Biological Products Co Ltd, H2 2017
Diarrhea - Dormant Projects, H2 2017
Diarrhea - Dormant Projects, H2 2017 (Contd..1), H2 2017
Diarrhea - Dormant Projects, H2 2017 (Contd..2), H2 2017
Diarrhea - Discontinued Products, H2 2017

LIST OF FIGURES

Number of Products under Development for Diarrhea, H2 2017
Number of Products under Development by Companies, H2 2017
Number of Products under Development by Universities/Institutes, H2 2017
Number of Products by Top 10 Targets, H2 2017
Number of Products by Stage and Top 10 Targets, H2 2017
Number of Products by Top 10 Mechanism of Actions, H2 2017
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017
Number of Products by Routes of Administration, H2 2017
Number of Products by Stage and Routes of Administration, H2 2017
Number of Products by Top 10 Molecule Types, H2 2017
Number of Products by Stage and Top 10 Molecule Types, H2 2017
Skip to top


Diarrhea - Pipeline Review, H1 2017 US$ 2,000.00 Feb, 2017 · 163 pages
Infectitious Diarrhea - Pipeline Review, H1 2014 US$ 2,000.00 May, 2014 · 76 pages
Infectitious Diarrhea - Pipeline Review, H2 2014 US$ 2,000.00 Nov, 2014 · 82 pages
Mucosis B.V. - Product Pipeline Review - 2015 US$ 1,500.00 Jul, 2015 · 27 pages
DiscoveryBiomed, Inc. - Product Pipeline Review - 2015 US$ 1,500.00 Jun, 2015 · 21 pages

Ask Your Question

Diarrhea - Pipeline Review, H2 2017
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: